Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEE
1751
DELISTED
Sealed Air
SEE
| $20.7M | 0.01% |
+358,070
| New | +$22.6M |
|
1752
CALL
ARK Genomic Revolution ETF
ARKG
$1.74B
| $20.6M | 0.01% |
655,000
-20,300
| -3% | -$710K |
|
1753
Gray Television
GTN
$538M
| $20.5M | 0.01% |
1,216,596
+449,329
| +59% | +$8.73M |
|
|
GTM
1754
PUT
ZoomInfo Technologies
GTM
$1.18B
| $20.5M | 0.01% |
617,500
+347,700
| +129% | +$15.3M |
|
1755
RLI Corp
RLI
$5.85B
| $20.5M | 0.01% |
352,092
+6,392
| +2% | +$366K |
|
1756
CALL
ProShares UltraPro S&P 500
UPRO
$5.82B
| $20.5M | 0.01% |
588,600
+262,100
| +80% | +$12.2M |
|
1757
CNX Resources
CNX
$5.28B
| $20.5M | 0.01% |
1,244,850
+1,222,115
| +5,375% | +$25M |
|
1758
Vanguard International Dividend Appreciation ETF
VIGI
$9.29B
| $20.5M | 0.01% |
298,200
+74,777
| +33% | +$5.48M |
|
|
CNR
1759
Core Natural Resources Inc
CNR
$4.76B
| $20.4M | 0.01% |
414,149
+337,683
| +442% | +$16.4M |
|
|
SJIV
1760
DELISTED
South Jersey Industries, Inc. Corporate Units
SJIV
| $20.4M | 0.01% |
300,592
-1
| -0% | -$69 |
|
1761
CALL
Canadian Natural Resources
CNQ
$98.9B
| $20.4M | 0.01% |
775,960
+63,302
| +9% | +$1.92M |
|
1762
PUT
Direxion Daily Small Cap Bear 3x ETF
TZA
$196M
| $20.4M | 0.01% |
43,716
+31,846
| +268% | +$12.8M |
|
1763
Intellia Therapeutics
NTLA
$1.67B
| $20.4M | 0.01% |
393,938
-92,495
| -19% | -$4.7M |
|
1764
PUT
IQVIA
IQV
$39B
| $20.4M | 0.01% |
93,900
+34,100
| +57% | +$7.41M |
|
|
1765
CALL
ResMed
RMD
$32.6B
| $20.3M | 0.01% |
97,000
-26,100
| -21% | -$5.56M |
|
1766
Insperity
NSP
$1.99B
| $20.3M | 0.01% |
203,404
+89,269
| +78% | +$8.84M |
|
1767
LendingTree
TREE
$458M
| $20.3M | 0.01% |
462,917
+133,047
| +40% | +$9.86M |
|
|
RXRA
1768
DELISTED
RXR Acquisition Corp. Class A Common Stock
RXRA
| $20.3M | 0.01% |
2,071,530
+70,077
| +4% | +$686K |
|
1769
Principal Financial Group
PFG
$24.4B
| $20.3M | 0.01% |
303,429
+241,976
| +394% | +$17M |
|
|
NVO
1770
PUT
Novo Nordisk
NVO
$201B
| $20.2M | 0.01% |
363,200
+16,200
| +5% | +$899K |
|
1771
Eagle Materials
EXP
$6.4B
| $20.2M | 0.01% |
183,884
+110,656
| +151% | +$13.6M |
|
1772
Edgewise Therapeutics
EWTX
$4.8B
| $20.2M | 0.01% |
2,538,018
-101,782
| -4% | -$769K |
|
1773
Trade Desk
TTD
$6.64B
| $20.2M | 0.01% |
481,896
+20,657
| +4% | +$1.13M |
|
1774
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.5B
| $20.2M | 0.01% |
395,255
+386,774
| +4,560% | +$20.2M |
|
|
NSTB
1775
DELISTED
Northern Star Investment Corp. II
NSTB
| $20.1M | 0.01% |
2,047,900
-1,129,253
| -36% | -$11.1M |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.